研究
11-10-2024
The 20-Year Experience of San Raffaele in Pancreatic Islet Transplants Strengthens the Path for Cell Therapies in Type 1 Diabetes
出版日期: 27-02-2025
更新日期: 27-02-2025
主题: 研究
预计阅读时间: 1 分钟
医学编辑
Lorenzo Piemonti
编辑和译员
Anastasiia ByvaltcevaA study analyzing the long-term outcomes of pancreatic islet transplantation in patients with type 1 diabetes treated at IRCCS Ospedale San Raffaele from 2001 to 2023 has been published in the prestigious journal The Lancet Diabetes & Endocrinology.
Coordinated by Professor Lorenzo Piemonti, Head of the Regenerative Medicine and Transplant Unit, Director of the Diabetes Research Institute at Ospedale San Raffaele, and Professor of Endocrinology at UniSR Università Vita-Salute San Raffaele, the study represents one of the world's largest single-center retrospective analyses, with a twenty-year follow-up. It provides crucial insights for future beta-cell replacement therapies in patients with type 1 diabetes.
Main Results of the Study
The analysis involved 79 patients aged 18 to 67 years and revealed that in individuals with type 1 diabetes treated with a pancreatic islet dose of at least 10,000 IEQ/kg and the αCD25/FK506/Rapa immunosuppressive protocol, the following outcomes were achieved:
- A significant improvement in transplant survival;
- Greater independence from insulin.
In this group, the median islet survival was 9.7 years, with 72.7% of patients remaining insulin-independent for 6 to 7 years.
Overall, the data show a transplant survival rate of 86% at one year, 65% at five years, and 40% at twenty years, confirming the long-term effectiveness of the treatment.
However, the study also highlighted some side effects associated with immunosuppressive therapy, such as infections and reduced kidney function, which require careful monitoring and targeted interventions to ensure long-term patient safety.
“This study highlights the potential of islet transplantation to improve the long-term quality of life for diabetes patients while providing valuable insights for optimizing future cell therapies, particularly those based on pancreatic islet differentiation from stem cells,” said Professor Lorenzo Piemonti.
“The findings not only help us better understand the effects of immunosuppression but also determine the optimal islet doses needed to ensure safe and effective transplants.
These results emphasize the importance of continuing research to enhance and refine cell therapies for type 1 diabetes patients, ensuring increasingly effective and sustainable treatments over the long term,” concluded Professor Piemonti.